The long-standing edge that Novo Nordisk has held in the obesity drug market was thrown into question Friday when the company reported results of a closely watched candidate that fell short of expectations.
Novo reported that, in a late-stage study, a next-generation obesity drug called CagriSema led patients to lose 20% of their weight at 68 weeks when looking at all participants — less than the company’s own projection of about 25% weight loss. Novo’s stock had tanked by nearly 18% midday Friday.
Investors had high hopes for CagriSema — a combination of semaglutide, the active ingredient in popular treatments Ozempic and Wegovy, and cagrilintide, a treatment that activates amylin and calcitonin receptors. The readout will likely exacerbate concerns about Novo’s ability to follow up on the success of blockbusters Ozempic and Wegovy.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in